S 1095 · 119th Congress 2025โ€“2027

Stop STALLING Act

Latest action · Apr 10, 2025 Placed on Senate Legislative Calendar under General Orders. Calendar No. 45.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedMar 24, 2025
  2. Passed SenateNot reached
  3. Passed HouseNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act

This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.

The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit is subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.

Cosponsors 6

Members who signed on, in the order they did. All signed on Mar 24, 2025.

SeatCosponsorSigned on
R-IAChuck GrassleyOriginalMar 24, 2025
D-NJCory A. BookerOriginalMar 24, 2025
D-VTPeter WelchOriginalMar 24, 2025
D-CTRichard BlumenthalOriginalMar 24, 2025
D-ILRichard J. DurbinOriginalMar 24, 2025
R-TXTed CruzOriginalMar 24, 2025

Committees 1

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
SenateJudiciary Committee
Referred Mar 24, 2025Markup Apr 3, 2025Reported Apr 10, 2025

Actions 5

Everything that happened, newest first.

  1. Apr 10, 2025Committee on the Judiciary. Reported by Senator Grassley without amendment. Without written report.
  2. Apr 10, 2025Placed on Senate Legislative Calendar under General Orders. Calendar No. 45.
  3. Apr 3, 2025Committee on the Judiciary. Ordered to be reported without amendment favorably.
  4. Mar 24, 2025Introduced in Senate
  5. Mar 24, 2025Read twice and referred to the Committee on the Judiciary.

Titles 5

Every title it has carried, official and short, at each stage.

Official Title as Introduced
A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes.
Short Title(s) as Introduced
Stop STALLING Act
Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act
Short Title(s) as Reported to Senate
Stop STALLING Act
Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 2

Each version as it was printed, newest first.

  1. Apr 10, 2025Reported to Senate
  2. Mar 24, 2025Introduced in Senate

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details.

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.